U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Anal Squamous Cell Carcinoma

MedGen UID:
1766830
•Concept ID:
C5418300
•
Neoplastic Process

Definition

The reemergence of anal squamous cell carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Anal Squamous Cell Carcinoma

Professional guidelines

PubMed

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K
J Natl Compr Canc Netw 2023 Jun;21(6):653-677. doi: 10.6004/jnccn.2023.0030. PMID: 37308125
Follow-up imaging of anal cancer after treatment.
El Homsi M, Sheedy SP, Rauch GM, Ganeshan DM, Ernst RD, Golia Pernicka JS
Abdom Radiol (NY) 2023 Sep;48(9):2888-2897. Epub 2023 Apr 6 doi: 10.1007/s00261-023-03895-0. PMID: 37024606
Experimental and investigational drugs for the treatment of anal cancer.
Jacome AA, Eng C
Expert Opin Investig Drugs 2018 Dec;27(12):941-950. Epub 2018 Nov 8 doi: 10.1080/13543784.2018.1543659. PMID: 30381968

Recent clinical studies

Etiology

Perineal Reconstruction With the Profunda Artery Perforator Flap.
Arquette C, Wan D, Momeni A
Ann Plast Surg 2022 Apr 1;88(4):434-439. doi: 10.1097/SAP.0000000000002986. PMID: 34510081
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
Rogers JE, Jácome AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng C
Expert Rev Anticancer Ther 2020 Oct;20(10):901-908. Epub 2020 Sep 2 doi: 10.1080/14737140.2020.1810573. PMID: 32799569
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C
BMC Cancer 2020 Apr 25;20(1):352. doi: 10.1186/s12885-020-06841-1. PMID: 32334548Free PMC Article
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C
Lancet Oncol 2018 Aug;19(8):1094-1106. Epub 2018 Jul 2 doi: 10.1016/S1470-2045(18)30321-8. PMID: 30042063
Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
Cunin L, Alfa-Wali M, Turner J, Bower M, Ion L, Allen-Mersh T
Ann Surg Oncol 2014 Feb;21(2):527-32. Epub 2013 Nov 18 doi: 10.1245/s10434-013-3353-3. PMID: 24242676

Diagnosis

Perineal Reconstruction With the Profunda Artery Perforator Flap.
Arquette C, Wan D, Momeni A
Ann Plast Surg 2022 Apr 1;88(4):434-439. doi: 10.1097/SAP.0000000000002986. PMID: 34510081
Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do?
Tremblay JF, Molina JM, Pocard M
J Visc Surg 2018 Feb;155(1):79-81. doi: 10.1016/j.jviscsurg.2017.10.010. PMID: 29100741
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C
BMC Cancer 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0. PMID: 28841909Free PMC Article
Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.
Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D, Boland PM
Oncotarget 2015 Dec 22;6(41):43594-604. doi: 10.18632/oncotarget.6202. PMID: 26498363Free PMC Article
Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
Cunin L, Alfa-Wali M, Turner J, Bower M, Ion L, Allen-Mersh T
Ann Surg Oncol 2014 Feb;21(2):527-32. Epub 2013 Nov 18 doi: 10.1245/s10434-013-3353-3. PMID: 24242676

Therapy

Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
Rogers JE, Jácome AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng C
Expert Rev Anticancer Ther 2020 Oct;20(10):901-908. Epub 2020 Sep 2 doi: 10.1080/14737140.2020.1810573. PMID: 32799569
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C
BMC Cancer 2020 Apr 25;20(1):352. doi: 10.1186/s12885-020-06841-1. PMID: 32334548Free PMC Article
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C
Lancet Oncol 2018 Aug;19(8):1094-1106. Epub 2018 Jul 2 doi: 10.1016/S1470-2045(18)30321-8. PMID: 30042063
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C
BMC Cancer 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0. PMID: 28841909Free PMC Article
Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
Cunin L, Alfa-Wali M, Turner J, Bower M, Ion L, Allen-Mersh T
Ann Surg Oncol 2014 Feb;21(2):527-32. Epub 2013 Nov 18 doi: 10.1245/s10434-013-3353-3. PMID: 24242676

Prognosis

Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
Rogers JE, Jácome AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng C
Expert Rev Anticancer Ther 2020 Oct;20(10):901-908. Epub 2020 Sep 2 doi: 10.1080/14737140.2020.1810573. PMID: 32799569
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C
BMC Cancer 2020 Apr 25;20(1):352. doi: 10.1186/s12885-020-06841-1. PMID: 32334548Free PMC Article
Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation.
Osborne EM, Eng C, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Nancy You YQ, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P
Am J Clin Oncol 2018 Jul;41(7):632-637. doi: 10.1097/COC.0000000000000338. PMID: 27755060
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C
BMC Cancer 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0. PMID: 28841909Free PMC Article
Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
Cunin L, Alfa-Wali M, Turner J, Bower M, Ion L, Allen-Mersh T
Ann Surg Oncol 2014 Feb;21(2):527-32. Epub 2013 Nov 18 doi: 10.1245/s10434-013-3353-3. PMID: 24242676

Clinical prediction guides

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C
Lancet Oncol 2018 Aug;19(8):1094-1106. Epub 2018 Jul 2 doi: 10.1016/S1470-2045(18)30321-8. PMID: 30042063
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C
BMC Cancer 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0. PMID: 28841909Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...